Description
Study KER-012-A201 is Phase 2, double-blind, randomized, placebo-controlled study to determine the efficacy and safety of KER-012 compared to Placebo in adults with PAH (WHO Group 1 PH) on stable background PAH therapy. The study is divided into the Screening Period, Treatment Period, Extension Period, and Follow-Up Period. The design of this study will control bias in the assignment of study treatment as well as in data interpretation, particularly of the measures that may have clinical variability (e.g., PVR and 6-minute walk distance [6MWD])
